Merck Terminates Odanacatib Trial Early on Positive Results
Some investors were puzzled when shares of Quest Diagnostics Inc. surged nearly 5 percent Thursday morning for apparently no reason. They could hardly be blamed for not knowing that Madison, N.J.-based Quest is entitled to a rather large payday upon commercialization of Merck & Co. Inc.'s odanacatib, which just blasted through its Phase III study goals upon interim analysis.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter